Important note: Information in this article was accurate in September 2005. The state of the art may have changed since the publication date.
 |
HIV Treatment Bulletin - Vol. 6, No. 9, September 2005
Data are limited for children under 2 years of age treated with HAART.
A study from Konigs and co-workers In Frankfurt followed five young children that had initiated LPV/r containing therapy for up to 18 months.
The average age at initiation of therapy was 8.5 months (range: 1.2-22.0 months) and all children received AZT/3TC/LPV/r in liquid formulations. The LPV/r dose was 230mg/m2 BID.
At baseline 4/5 children had a viral load >1,000,000 copies/mL. This decreased by 2 logs within 2 to 4 weeks, after which the decrease was less rapid and reached <100 copies/mL after 6 to 10 months, with 1 child achieving <20 copies/mL.
CD4 counts remained stable for children initiating therapy earlier but immunocompromised children showed an increase from 23 to 36%.
The authors reported that LPV/r plasma levels were lower than has been described for older age groups. The average minimal concentration at I hour after administration was 1355 ng/mL and at three hours after administration it was 2804 ng/mL.
They noted that the children initially had difficulties with the LPV/r due to the taste of the formulation but once they got used to it, the children tolerated it well. Using LPV/r in HIV treatment regimens in children <2 years with high viral loads leads to a rapid drop and an increase in CD4 counts.
They suggest that observed low plasma levels should give rise to further studies evaluation dose adjustment for children below 2 years of age.
Comment
This study is tiny so it is difficult to comment on efficacy. More data on this drug in infants is urgently needed though as some guidelines (South Africa’s for example) are recommending LPV/r for infant first line therapy out of concern that their mothers may have been exposed to single dose nevirapine in MTCT programmes. The PK suggests this needs further investigation.
Ref: Konigs C, Dunsch D, von Hentig N et al. LPV/r (Kaletra) in children younger than 24 months – rapid decrease in viral load and stable CD4 counts despite very low plasma levels. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd: (Abstract No. MoPe9.2C11).
050910
IB050609-06
©2005. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.
